Clinuvel Pharmaceuticals Limited
CLVLF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $549 | $756 | $890 | $698 |
| - Cash | $224 | $184 | $157 | $122 |
| + Debt | $1 | $1 | $1 | $1 |
| Enterprise Value | $326 | $573 | $734 | $578 |
| Revenue | $95 | $88 | $78 | $66 |
| % Growth | 7.8% | 12.6% | 19.2% | – |
| Gross Profit | $79 | $80 | $70 | $55 |
| % Margin | 83.3% | 91.2% | 88.8% | 84% |
| EBITDA | $57 | $56 | $50 | $37 |
| % Margin | 60.2% | 63.8% | 63.3% | 56.8% |
| Net Income | $36 | $36 | $31 | $21 |
| % Margin | 38.1% | 40.4% | 39.1% | 31.8% |
| EPS Diluted | 0.72 | 0.7 | 0.59 | 0.4 |
| % Growth | 2.9% | 18.6% | 47.5% | – |
| Operating Cash Flow | $41 | $37 | $37 | $40 |
| Capital Expenditures | -$0 | -$6 | -$1 | -$0 |
| Free Cash Flow | $41 | $31 | $36 | $39 |